Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With Acute Coronary Syndrome Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2).

Trial Profile

Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With Acute Coronary Syndrome Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2).

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2008

At a glance

  • Drugs Abciximab (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery restenosis; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms ISAR-REACT-2
  • Most Recent Events

    • 15 Nov 2007 New trial centres added.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top